Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Assess the Safety, Tolerability, PK/PD, and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies

NCT06314373 is registered in ClinicalTrials.gov with Xizang Haisco Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06314373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06314373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Assess the Safety, Tolerability, PK/PD, and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies
Lead sponsor
Xizang Haisco Pharmaceutical Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 7, 2024
Completion date
September 1, 2028
Enrollment
243 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors